免疫检查点抑制剂在实体瘤中的应用  

Immune checkpoint inhibitors in solid tumors

作　　者：耿瑞璇 郑志博 戴晓艳[1] 张志媛[1] 司文洁[1] 付晨薇[1] 田庄[1] 李永宁[1] GENG RuiXuan;ZHENG ZhiBo;DAI XiaoYan;ZHANG ZhiYuan;SI WenJie;FU ChenWei;TIAN Zhuang;LI YongNing(International Medical Services,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China)

机构地区：[1]中国医学科学院&北京协和医学院,北京协和医院国际医疗部,北京100730

出　　处：《中国科学：生命科学》2021年第8期1180-1192,共13页Scientia Sinica(Vitae)

摘　　要：免疫系统在肿瘤的治疗中有重要作用.以单克隆抗体为代表的免疫检查点抑制剂在抗肿瘤领域中取得了成功,改变了肿瘤治疗的格局.本文对细胞毒性T淋巴细胞相关抗原4(cytotoxic T lymphocyte-associated antigen 4,CTLA-4)、程序性细胞死亡蛋白1(programmed cell death protein 1 pathway,PD-1/PD-L1)通路、新型免疫检查点分子及相关免疫检查点抑制剂进行综述,总结了免疫检查点抑制剂的临床应用价值、免疫检查点抑制剂治疗带来的免疫相关不良反应.寻找优势人群、处理免疫相关不良反应、克服药物耐药,是目前该领域需要解决的问题.The immune system plays an important role in the treatment of tumors.Immune checkpoint inhibitors represented by monoclonal antibodies have achieved success in the field of anti-tumor and changed the pattern of tumor treatment.In this paper,we review immune checkpoint inhibitors of cytotoxic T lymphocyte associated antigen 4(CTLA-4),programmed cell death protein 1(PD1/PDL1)pathway,and new immune checkpoint targets.We also summarize the clinical applications and immune-related adverse events(irAEs)of immune checkpoint inhibitors.Key problems remain to be solved,such as how to identify the benefit population,how to manage irAEs better,and how to overcome drug resistance.

关 键 词：免疫检查点抑制剂 CTLA-4 PD-1 PD-L1 免疫相关不良反应 

分 类 号：R730.51[医药卫生—肿瘤]